Lifesci Capital Predicts Upstream Bio Q2 Earnings

Upstream Bio, Inc. (NASDAQ:UPB) – Stock analysts at Lifesci Capital issued their Q2 2026 earnings estimates for Upstream Bio in a note issued to investors on Tuesday, March 3rd. Lifesci Capital analyst K. Dellorusso expects that the company will post earnings of ($0.69) per share for the quarter. Lifesci Capital has a “Outperform” rating and a $43.00 price objective on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($4.30) per share. Lifesci Capital also issued estimates for Upstream Bio’s Q3 2026 earnings at ($0.65) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($3.05) EPS.

A number of other equities research analysts also recently weighed in on UPB. Evercore started coverage on Upstream Bio in a research report on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price target on the stock. Mizuho raised Upstream Bio to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.25.

Upstream Bio Stock Down 1.7%

Shares of NASDAQ UPB opened at $7.67 on Friday. The company has a market cap of $414.49 million, a P/E ratio of -4.08 and a beta of 2.96. Upstream Bio has a 52 week low of $5.14 and a 52 week high of $33.68. The business has a 50-day simple moving average of $22.35 and a two-hundred day simple moving average of $22.36.

Institutional Investors Weigh In On Upstream Bio

A number of hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its holdings in Upstream Bio by 6.4% in the second quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock valued at $179,000 after acquiring an additional 985 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Upstream Bio in the fourth quarter worth approximately $29,000. Torren Management LLC bought a new stake in Upstream Bio during the fourth quarter valued at approximately $30,000. JPMorgan Chase & Co. increased its holdings in Upstream Bio by 8.4% during the second quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock valued at $181,000 after buying an additional 1,275 shares during the last quarter. Finally, Rhumbline Advisers raised its position in Upstream Bio by 2.8% in the third quarter. Rhumbline Advisers now owns 49,406 shares of the company’s stock worth $929,000 after acquiring an additional 1,340 shares during the period.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.